Elutia Fully Exercises Warrants, Generating $15.7M in Gross Proceeds

Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today announced that it had received gross proceeds of approximately $15.7 million from the exercise of outstanding warrants to purchase common stock issued in a private placement financing completed in September 2023.